Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
PCBP1 N/A
Sequence Length (AA) Molecular Weight (Da)
356 37498
Protein Name
Poly(rC)-binding protein 1
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MDAGVTESGL NVTLTIRLLM HGKEVGSIIG KKGESVKRIR EESGARINIS
60 70 80 90 100
EGNCPERIIT LTGPTNAIFK AFAMIIDKLE EDINSSMTNS TAASRPPVTL
110 120 130 140 150
RLVVPATQCG SLIGKGGCKI KEIRESTGAQ VQVAGDMLPN STERAITIAG
160 170 180 190 200
VPQSVTECVK QICLVMLETL SQSPQGRVMT IPYQPMPASS PVICAGGQDR
210 220 230 240 250
CSDAAGYPHA THDLEGPPLD AYSIQGQHTI SPLDLAKLNQ VARQQSHFAM
260 270 280 290 300
MHGGTGFAGI DSSSPEVKGY WASLDASTQT THELTIPNNL IGCIIGRQGA
310 320 330 340 350
NINEIRQMSG AQIKIANPVE GSSGRQVTIT GSAASISLAQ YLINARLSSE
356
KGMGCS

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-417 Collapse assay details

Data source: Panorama

Official Gene Symbol
PCBP1
Peptide Sequence
IITLTGPTNAIFK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
58
Peptide End
70
CPTAC ID
CPTAC-417
Peptide Molecular Mass
1,387.8075
Species
Homo sapiens (Human)
Assay Type
Direct MRM-MS
Matrix
cell line lysate pool
Submitting Laboratory
Broad Institute and FHCRC
Submitting Lab PI
Steve Carr

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
5500 QTRAP (ABSCIEX)
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)
Column Packing
ChromXP C18-CL, 3 um, 120A
Column Dimensions
150 x 0.075 mm
Flow Rate
500 nL / min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y11 (1+) 10.8 4.9 2.9 15.7 6.2 5.1 19.1 7.9 5.9 15 25 15
y9 (1+) 13.2 4.9 3 17.5 5.9 5.3 21.9 7.7 6.1 15 25 15
y8 (1+) 25.1 5.2 2.2 30.8 6.2 4.6 39.7 8.1 5.1 15 25 15
sum 14.2 4.6 2.1 19 5.7 4.6 23.7 7.3 5.1 15 25 15


Additional Resources and Comments


Assay Details for CPTAC-418 Collapse assay details

Data source: Panorama

Official Gene Symbol
PCBP1
Peptide Modified Sequence
LVVPATQC[+57.0]GSLIGK
Modification Type
Carbamidomethyl Cysteine
Protein - Site of Modification
109
Peptide - Site of Modification
8
Peptide Start
102
Peptide End
115
CPTAC ID
CPTAC-418
Peptide Molecular Mass
1,441.7963
Species
Homo sapiens (Human)
Assay Type
Direct MRM-MS
Matrix
cell line lysate pool
Submitting Laboratory
Broad Institute and FHCRC
Submitting Lab PI
Steve Carr

Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
5500 QTRAP (ABSCIEX)
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C,15N
LC
nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)
Column Packing
ChromXP C18-CL, 3 um, 120A
Column Dimensions
150 x 0.075 mm
Flow Rate
500 nL / min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y11 (1+) 12.3 7.6 6.8 17.7 9.5 9.2 21.6 12.2 11.4 15 25 15
y9 (1+) 21.9 9 3.4 23.5 10.1 3.5 32.1 13.5 4.9 15 25 15
y7 (1+) 36.1 11.1 5.6 38.2 12 7.7 52.6 16.3 9.5 15 25 15
sum 13.9 7.1 5.7 16.9 8.9 7.6 21.9 11.4 9.5 15 25 15


Additional Resources and Comments


Assay Details for non-CPTAC-6113 Collapse assay details

Data source: Panorama

Official Gene Symbol
PCBP1
Peptide Sequence
IITLTGPTNAIFK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
58
Peptide End
70
CPTAC ID
non-CPTAC-6113
Peptide Molecular Mass
1,387.8075
Species
Homo sapiens (Human)
Assay Type
Direct MRM-MS
Matrix
Bovine Serum Albumin
Submitting Laboratory
McGill University
Submitting Lab PI
Christoph H. Borchers, Gerald Batist

Publication

View Details (opens in a new window)

mTORC1-driven protein translation correlates with clinical benefit of capivasertib within a genetically preselected cohort of PIK3CA-altered tumours. Constance A Sobsey, Bjoern C Froehlich, Georgia Mitsa, Sahar Ibrahim, Robert Popp, Rene P Zahedi, Elza C de Bruin, Christoph H Borchers, Gerald Batist


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Agilent 6495B QQQ-MS
Internal Standard
Standard Isotope labeled internal standard peptides with 13Cx, 15Ny (R+10 or K+8)
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Infinity 1290
Column Packing
commercial (Agilent ZORBAX Eclipse Plus C18)
Column Dimensions
4.6 mm × 150 mm, (5 µm)
Flow Rate
0.4 mL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b3 (1+) 6.6 3.5 3 6.8 3.4 3.3 9.5 4.9 4.5 16 16 17
y11 (1+) 5.7 2.3 3 4 3.1 3.1 7 3.9 4.3 16 16 17
y8 (1+) 6 1.9 2.6 5 3.2 2.6 7.8 3.7 3.7 16 16 17
y9 (1+) 6.3 3.6 5.3 5.1 3.2 5.9 8.1 4.8 7.9 16 16 17
b2 (1+) NA NA NA NA NA NA NA NA NA 0 0 0
sum 3.1 1.4 1.5 1.7 1.2 1.5 3.5 1.8 2.1 16 16 17


Stability

Data source: Panorama

Fragment ion / Transition control_intra_CV actual_temp_intra_CV frozen_intra_CV FTx1_intra_CV FTx2_intra_CV
b3 (1+) 1.6 3.5 2.8 2.9 1.2
y11 (1+) 3.9 1.9 2.9 2 2.7
y8 (1+) 3.3 4.2 2 5.6 4.6
y9 (1+) 4.5 1.8 1.7 3.9 1.2
sum 1.1 1.7 0.8 1.2 1.9
Fragment ion / Transition all_intra_CV all_inter_CV
b3 (1+) 2.6 3.3
y11 (1+) 2.6 3.8
y8 (1+) 4 2.9
y9 (1+) 2.5 4.1
sum 1.4 1.2

Endogenous

Data source: Panorama

Fragment ion / Transition intra_CV inter_CV total_CV
b3 (1+) 2 24.5 24.6
y11 (1+) 0.5 20.1 20.1
y8 (1+) 1.9 21.8 21.9
y9 (1+) 1.4 22.3 22.3
b2 (1+) NA NA NA
sum 0.4 21.8 21.8

Additional Resources and Comments